General Biologicals's latest marketcap:
As of 07/17/2026, General Biologicals's market capitalization has reached $25.65 M. According to our data, General Biologicals is the 35755th most valuable company globally by market capitalization. Market capitalization, commonly referred to as market cap, represents the total market value of all outstanding shares of a publicly traded company and is often used as a measure of company value.
| Market Cap | 25.65 M |
| Revenue (ttm) | 6.68 M |
| Net Income (ttm) | 14.42 M |
| Shares Out | 70.82 M |
| EPS (ttm) | 0.23 |
| Forward PE | 0.00 |
| Ex-Dividend Date | n/a |
| Earnings Date | 08/12/2026 |
General Biologicals's yearly market capitalization.
| Date | Market Cap(NT$) | Market Cap(USD) | Change (%) | Global Rank |
|---|---|---|---|---|
| 07/17/2026 | NT$828.65 M | $25.65 M | 12.06% | 35755 |
| 12/31/2025 | NT$781.6 M | $24.89 M | -38.66% | 30345 |
| 12/31/2024 | NT$1.27 B | $38.8 M | -21.11% | 29757 |
| 12/29/2023 | NT$1.62 B | $52.54 M | 0.37% | 27423 |
| 12/30/2022 | NT$1.61 B | $52.54 M | -22.7% | 26521 |
| 12/30/2021 | NT$2.08 B | $75.09 M | -35.56% | 24997 |
| 12/31/2020 | NT$3.23 B | $0 | 609.23% | 19812 |
| 12/31/2019 | NT$455.5 M | $15.2 M | -3.27% | 27458 |
| 12/28/2018 | NT$470.91 M | $15.38 M | -21.08% | 26430 |
| 12/29/2017 | NT$596.69 M | $20.08 M | -17.36% | 25487 |
Company Profile
About General Biologicals Corporation
General Biologicals Corporation is a leading biotechnology company specializing in the research, development, manufacturing, and sales of in-vitro diagnostics. Headquartered in Hsinchu City, Taiwan, the company has been serving the global healthcare industry since its founding in 1973.
Core Products and Services
- Diagnostic Solutions: ELISA, chemiluminescence immunoassay, molecular and cell diagnostics, and point-of-care testing services.
- Specialized Testing: COVID-19 diagnostics, digital pathology solutions, and contract development manufacturing organization (CDMO) services.
- Blood Screening: Services for hepatitis, HIV, and other infectious diseases.
- Biomaterials: Antibody biomaterials and human plasma for research and clinical applications.
- Oral Care Products: A range of premium oral care solutions under the oh care brand.
Market Reach
The company delivers its diagnostic solutions to clinics and laboratories across Taiwan and international markets, ensuring high-quality healthcare support worldwide.
With decades of expertise, General Biologicals Corporation continues to innovate and expand its contributions to the medical and biotechnology sectors.
Frequently Asked Questions
-
What is General Biologicals's (TPEX-4117) current market cap?As of 07/17/2026, General Biologicals (including the parent company, if applicable) has an estimated market capitalization of $25.65 M USD. This figure represents the total market value of its outstanding shares, including different share classes. Please note that market capitalization fluctuates based on market conditions, and the actual valuation may differ from the latest estimate.
-
Where does General Biologicals (TPEX-4117) rank globally by market cap?General Biologicals global market capitalization ranking is approximately 35755 as of 07/17/2026. This ranking is relative to all publicly traded companies worldwide and can fluctuate based on market dynamics and the performance of other companies. You can refer to our Global companies market cap ranking for the most up-to-date ranking.